Scarica l'app Stockscreener
113.56
3.45%
-4.06
Dopo l'orario di chiusura:
113.60
0.04
+0.04%
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp - MarketBeat
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Citizens Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform Recommendation - Nasdaq
Canaccord Genuity Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
RYTM Stock: Canaccord Genuity Raises Price Target to $141, Maint - GuruFocus
Goldman Sachs Raises Price Target for RYTM to $157, Maintains Buy Rating | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on positive PWS data - Investing.com Canada
Rhythm Pharma Surprises With Encouraging PWS Drug Trial Results - Finimize
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says - marketscreener.com
RYTM Analyst Rating Update: Citizens Raises Price Target to $167 - GuruFocus
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating - marketscreener.com
Rhythm Pharmaceuticals stock price target raised to $167 at Citizens By Investing.com - Investing.com Canada
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals stock price target raised to $167 at Citizens - Investing.com India
Rhythm Pharmaceuticals stock jumps as Goldman Sachs raises price target on PWS study - Investing.com Canada
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans - Yahoo Finance
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? - Yahoo Finance
Growth or Bubble? Exploring Rhythm’s Recent Surge - StocksToTrade
Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD By Investing.com - Investing.com Canada
Needham Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharma Soars with Buy Rating and Optimistic Trials - StocksToTrade
Rhythm Pharmaceuticals’ Stock Surge: Buy Now? - timothysykes.com
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster (RYTM) - Seeking Alpha
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily
Rhythm Pharmaceuticals reports positive results in Prader-Willi trial By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals stock holds Buy rating at TD Cowen on PWS trial data - Investing.com Canada
Rhythm Pharmaceuticals Surges: Strategic Moves Fuel Market Buzz - timothysykes.com
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $145 | RYTM Stock News - GuruFocus
Morgan Stanley raises Rhythm Pharmaceuticals stock price target to $150 By Investing.com - Investing.com UK
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise - Benzinga
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month HighHere's Why - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 1-Year HighWhat's Next? - MarketBeat
Rhythm Pharmaceuticals stock rises after positive study data for setmelanotide in treating genetic disorder - MSN
RYTM: Setmelanotide showed promising BMI and hyperphagia improvements in PWS, supporting phase 3 plans - TradingView
Rhythm Pharmaceuticals (RYTM) Soars Over 15% in Market Rally - GuruFocus
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder - Stocktwits
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Benzinga
Rhythm Pharmaceuticals (RYTM) Climbs Over 11% - GuruFocus
Citi Initiates Buy Coverage on Rhythm Pharmaceuticals with Price Target Set for Growth - timothysykes.com
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook - ts2.tech
Rhythm Pharmaceuticals Stock Climbs on Positive Trial News - TipRanks
Rhythm Pharmaceuticals stock soars after positive trial results By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals stock soars after positive trial results - Investing.com India
Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD - Investing.com
Rhythm Pharma rises on positive mid-stage data for rare disease therapy - TradingView — Track All Markets
Rhythm Pharmaceuticals reports positive results in Prader-Willi trial - Investing.com
Rhythm Pharmaceuticals Announces Preliminary Phase 2 Trial Results for Setmelanotide in PWS - TradingView — Track All Markets
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome - The Manila Times
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed ... - Enidnews.com
Rhythm Pharmaceuticals, Inc. to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome - marketscreener.com
Rhythm Pharma To Present Preliminary Phase 2 Data Of Setmelanotide In Prader-Willi Syndrome Today - RTTNews
Rhythm Pharmaceuticals to release PWS trial data on Thursday By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals to release PWS trial data on Thursday - Investing.com
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome - The Manila Times
Rhythm Pharmaceuticals to Host Conference Call for Preliminary Phase 2 Trial Data of Setmelanotide in Prader-Willi Syndrome - Quiver Quantitative
Rhythm Pharmaceuticals to Announce Preliminary Data from - GlobeNewswire
Rhythm Pharmaceuticals, Inc. $RYTM Position Increased by Stempoint Capital LP - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Marshall Wace LLP - MarketBeat
Norges Bank Invests $13.11 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Can Rhythm Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Hood River Capital Management LLC Cuts Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):